9th Antigen-Specific Immune Tolerance Summit

Uniting 60+ leaders from cutting-edge biotechs to global pharma, this summit delivers comprehensive insight across antigen selection, biomarker strategy, B-cell and cellular tolerance mechanisms, delivery platforms, and clinical trial execution.

The 2026 agenda spotlights late-stage data from Topas, Diamyd, and COUR; novel mRNA- LNP approaches from Moderna; integrated nanotherapeutics; and next-generation Treg and tolerance-restoring strategies. Key sessions explore central versus peripheral tolerance, and how gene and cell therapy are redefining therapeutic durability and safety.

Now in its ninth year, the 9th Antigen-Specific Immune Tolerance Summit remains the only end-to-end meeting dedicated to advancing antigen-specific immune tolerance. Join Pfizer, Moderna, AbbVie, Diamyd, COUR, and others as the field transitions from discovery and preclinical efforts to real-world clinical impact. Seize the opportunity to and play a central role in rewriting these transformative therapeutics